Screening for EGFR mutations in lung cancer, a report from India

Lung Cancer

Volumn 73, Issue 3, 2011, Pages 316-319

  Sahoo, Rashmita ^a   V, Vidya Harini ^a   Babu, V Chitti ^a   V Patil Okaly, Geeta ^a   Rao, Smitha ^a   Nargund, Ashwini ^a   Venkataswamy, E ^a   Rao, Raghavendra ^b   Kumar, B S Ajai ^b  

^a Triesta Sciences (I) Private Limited   (India)

^b HCG Foundation   (India)

Author keywords

ARMS PCR; EGFR mutation; Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER SCREENING; CYTOLOGY; DISEASE COURSE; DNA EXTRACTION; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; INDIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MISSENSE MUTATION; PLEURA FLUID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR BIOPSY;

AGE FACTORS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; HUMANS; INDIA; LUNG NEOPLASMS; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SEX FACTORS;

EID: 79960860845     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.004     Document Type: Article

References (26)

1. Sawyers C.L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003, 17(December (24)):2998-3010.
2. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(August (7)):472-480.
3. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344(April (14)):1038-1042. Erratum in: N Engl J Med 2001 Jul 19;345(3):232.
4. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(March (11)):783-875.
5. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20(18 Suppl.):1S-13S.
6. Dina K., Patel Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008, 28(11-supp):31S-41S.
7. Rivera F., Vega-Villegas M.E., López-Brea M.F. Cetuximab: its clinical use and future perspectives. Anticancer Drugs 2008, 19(February (2)):99-113.
8. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77(6):400-410. Epub 2010 Feb 2.
9. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(June (5676)):1497-1500. Epub 2004 Apr 29.
10. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
11. Oxnard G.R., Miller V.A. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) 2010, 24(April (5)):392-401.
12. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361.
13. Kim T.-Y., Han S.-W., Bang Y.-J. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer. Asian perspectives Expert Review of Molecular Diagnostics 2007, 7(6):821-836.
14. EGFR Expression and Mutational Analysis As a Predictive Test, Dan J. Raz and David M. Jablons, JCO.2007.10.1733.
15. Ma B.B.Y., Hui E.P., Mok T.S.K. Population-based differences in treatment outcome following anticancer drug therapies. The Lancet Oncol 2010, 11(January (1)):75-84.
16. Kiri V.A., Soriano J., Visick G., Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J 2010, 19(March (1)):57-61. 10.1016/S1470-2045(09)70160-3.
17. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(September (36)):13306-13317. Epub 2004 Aug 25.
18. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8942.
19. Wang Y., Liu H., Chen J. The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs. Zhongguo Fei Ai Za Zhi 2010, 13(April (4)):375-379.
20. Xu Y., Chen L., Tian Q., Yang Z., Zhao W., Wang P., et al. Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2010, 13(January (1)):48-53.
21. Liu H., Li Y., Chen G., Wang J., Li Y., Wang Y., et al. Detection and its clinical significance of EGFR gene mutation and gene amplification in 187 patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12(December (12)):1219-1247.
22. Yang C.H. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008, 60(June (Suppl. 2)):S23-S30.
23. Carotenuto P., Roma C., Rachiglio A.M., Tatangelo F., Pinto C., Ciardiello F., et al. Detection of KRAS mutations in colorectal carcinomapatients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 2010, 11(8):1169-1179.
24. Cohen V., Agulnik J.S., Ang C., Kasymjanova G., Batist G., Small D., et al. Epidermal growth factor receptor mutations detected by denaturing high-performanceliquid chromatography in nonsmall cell lung cancer: impact on response to therapy withepidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 2010, 116(18):4215-4432.
25. Sumiyoshi K., Shibayama Y., Akashi S., et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections. Oncol Rep 2006, 15:803-808.
26. Wei1 E.X., Anga A.A., Martin S.S., Jackson J.G., Nordberg M.L., Herrera G.A., Turbat-Herrera E.A. EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens. Mod Pathol 2007, 20:905-913.